TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

Next-day discharge after TAVR is still safe when alternative access is required

Even TAVR patients not treated using transfemoral access can typically go home the very next day. 

Hemal Gada, MD, cardiologist

Q&A: Cardiologist and EARLY TAVR co-author questions study’s execution

The EARLY TAVR clinical trial made a significant impact, paving the way for the FDA to approve multiple transcatheter heart valves for the treatment of asymptomatic patients. However, one cardiologist who participated in the trial has some serious concerns with how its findings were presented to the public. 

cardiologists heart doctors heart research heart data

Balloon-expandable, self-expanding TAVR valves associated with comparable long-term outcomes

Patients treated with the Sapien 3 platform from Edwards Lifesciences and the Evolut platform from Medtronic were linked to more similarities than differences after six years. This was a single-center study, researchers noted, but it does provide an in-depth look at the safety and effectiveness of TAVR.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

TAVR specialists come together to explore new data, patient selection and much more

Care teams have a lot to consider when choosing the right treatment for patients with severe aortic stenosis. Two cardiologists and a veteran cardiothoracic surgeon are taking part in a new webinar focused on that very topic. 

Vinay Badhwar, MD, and his team perform a robotic TAVR explant and aortic valve replacement. Image courtesy of WVU Medicine.

Heart surgeons perform world’s first robotic TAVR explant and aortic valve replacement

The patient, 67, presented with a failing TAVR valve and a leaky mitral valve. She had undergone TAVR four years prior, but premature structural valve degeneration made a full replacement necessary. Surgeons ultimately removed the TAVR valve in addition to replacing her aortic and mitral valves—all with the help of advanced robotics.

cardiologist viewing heart data

Real-world data favor SAVR over TAVR when younger patients need aortic valve replacement

Researchers in Italy tracked data from more than 7,000 patients who underwent AVR between the ages of 65 and 80. TAVR was associated with a significantly higher long-term risk of mortality.

Newsweek ranked the 50 best heart hospitals in the world

Heart patients benefit when cardiologists follow a standardized TAVR protocol

Using a standardized approach, including the cusp overlap technique, is associated with improved patient outcomes when implanting Medtronic's self-expanding TAVR valves. Researchers tracked data from more than 600 patients treated all over the world, presenting their findings in JSCAI.

heart drugs with stethoscope

How anticoagulants may impact a patient’s risk of gastrointestinal bleeding after TAVR

Researchers tracked the rates of major gastrointestinal bleeding in patients with AFib randomized to receive edoxaban or a vitamin K antagonist after a successful TAVR procedure.

Displaying 9 - 16 of 506
Design by Adaptive Theme